Innate Pharma S.A. (NASDAQ:IPHA) Sees Large Decrease in Short Interest

Innate Pharma S.A. (NASDAQ:IPHA) saw a significant decrease in short interest in December. As of December 31st, there was short interest totalling 101,000 shares, a decrease of 88.9% from the December 15th total of 909,800 shares. Based on an average daily volume of 467,300 shares, the short-interest ratio is presently 0.2 days.

Analyst Ratings Changes

Several research analysts have recently commented on IPHA shares. Evercore ISI raised shares of Innate Pharma to a “strong-buy” rating in a research note on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $11.50 price target on shares of Innate Pharma in a research note on Monday, December 9th.

Innate Pharma Price Performance

NASDAQ IPHA traded up $0.05 during trading hours on Monday, hitting $1.82. 29,616 shares of the company were exchanged, compared to its average volume of 43,231. The company has a 50 day moving average of $1.80 and a two-hundred day moving average of $2.02. Innate Pharma has a 52-week low of $1.29 and a 52-week high of $3.51.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.